Angiogenesis meets immunology: Cytokine gene therapy of cancer

Molecular Aspects of Medicine

Volumn 28, Issue 1, 2007, Pages 59-86

  Minuzzo, Sonia ^a   Moserle, Lidia ^a   Indraccolo, Stefano ^b   Amadori, Alberto ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cancer; Cytokine; Gene therapy; IL 12; Interferon

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; B7 ANTIGEN; BETA INTERFERON; CD40 ANTIGEN; CYTOKINE; DNA; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSTIMULATING AGENT; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RAPAMYCIN DERIVATIVE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; CANCER GENE THERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; IMMUNOSTIMULATION; INFLAMMATORY CELL; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; REVIEW; TUMOR VASCULARIZATION;

ALLERGY AND IMMUNOLOGY; CYTOKINES; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33847314184     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2006.12.008     Document Type: Review

References (219)

1. Abdel-Wahab M., El-Shennawy F., Agha S., Ragab E., Fathi O., Sultan A., Elghawalby N., and Ezzat F. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2). Hepatogastroenterology 46 Suppl. 1 (1999) 1293-1296
2. Albini A., Marchisone C., Del Grosso F., Benelli R., Masiello L., Tacchetti C., Bono M., Ferrantini M., Rozera C., Truini M., Belardelli F., Santi L., and Noonan D.M. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am. J. Pathol. 156 4 (2000) 1381-1393
3. Allione A., Consalvo M., Nanni P., Lollini P.L., Cavallo F., Giovarelli M., Forni M., Gulino A., Colombo M.P., Dellabona P., et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res. 54 23 (1994) 6022-6026
4. Andersen M.H., Gehl J., Reker S., Pedersen L.O., Becker J.C., Geertsen P., and thor Straten P. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin. Cancer Biol. 13 6 (2003) 449-459
5. Angiolillo A.L., Sgadari C., Taub D.D., Liao F., Farber J.M., Maheshwari S., Kleinman H.K., Reaman G.H., and Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182 1 (1995) 155-162
6. Anichini A., Molla A., Mortarini R., Tragni G., Bersani I., Di Nicola M., Gianni A.M., Pilotti S., Dunbar R., Cerundolo V., and Parmiani G. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med. 190 5 (1999) 651-667
7. Apolloni E., Bronte V., Mazzoni A., Serafini P., Cabrelle A., Segal D.M., Young H.A., and Zanovello P. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 165 12 (2000) 6723-6730
8. Arienti F., Belli F., Napolitano F., Sule-Suso J., Mazzocchi A., Gallino G.F., Cattelan A., Santantonio C., Rivoltini L., Melani C., Colombo M.P., Cascinelli N., Maio M., and Parmiani G. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 10 18 (1999) 2907-2916
9. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 9255 (2001) 539-545
10. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 3 (2005) 211-217
11. Barajas M., Mazzolini G., Genove G., Bilbao R., Narvaiza I., Schmitz V., Sangro B., Melero I., Qian C., and Prieto J. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 33 1 (2001) 52-61
12. Beatty G., and Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J. Immunol. 166 4 (2001) 2276-2282
13. Belardelli F., and Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23 4 (2002) 201-208
14. Belardelli F., Ferrantini M., Santini S.M., Baccarini S., Proietti E., Colombo M.P., Sprent J., and Tough D.F. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Cancer Res. 58 24 (1998) 5795-5802
15. Benedict W.F., Tao Z., Kim C.S., Zhang X., Zhou J.H., Adam L., McConkey D.J., Papageorgiou A., Munsell M., Philopena J., Engler H., Demers W., Maneval D.C., Dinney C.P., and Connor R.J. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol. Ther. 10 3 (2004) 525-532
16. Bertolini F., Shaked Y., Mancuso P., and Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6 11 (2006) 835-845
17. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10 5 (1998) 383-390
18. Bowman L., Grossmann M., Rill D., Brown M., Zhong W.Y., Alexander B., Leimig T., Coustan-Smith E., Campana D., Jenkins J., Woods D., Kitchingman G., Vanin E., and Brenner M. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92 6 (1998) 1941-1949
19. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., Wolf S.F., and Gately M.K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178 4 (1993) 1223-1230
20. Bubenik J., Voitenok N.N., Kieler J., Prassolov V.S., Chumakov P.M., Bubenikova D., Simova J., and Jandlova T. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19 4 (1988) 279-282
21. Cao X., Zhang W., Wang J., Zhang M., Huang X., Hamada H., and Chen W. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 97 4 (1999) 616-625
22. Casares N., Arribillaga L., Sarobe P., Dotor J., Lopez-Diaz de Cerio A., Melero I., Prieto J., Borras-Cuesta F., and Lasarte J.J. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171 11 (2003) 5931-5939
23. Cavallo F., Giovarelli M., Gulino A., Vacca A., Stoppacciaro A., Modesti A., and Forni G. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 149 11 (1992) 3627-3635
24. Chada S., Ramesh R., and Mhashilkar A.M. Cytokine- and chemokine-based gene therapy for cancer. Curr. Opin. Mol. Ther. 5 5 (2003) 463-474
25. Chapoval A.I., Fuller J.A., Kremlev S.G., Kamdar S.J., and Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J. Immunol. 161 12 (1998) 6977-6984
26. Chen L., Ashe S., Brady W.A., Hellstrom I., Hellstrom K.E., Ledbetter J.A., McGowan P., and Linsley P.S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71 7 (1992) 1093-1102
27. Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellstrom I., and Hellstrom K.E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179 2 (1994) 523-532
28. Choi E.A., Lei H., Maron D.J., Mick R., Barsoum J., Yu Q.C., Fraker D.L., Wilson J.M., and Spitz F.R. Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. Clin. Cancer. Res. 10 4 (2004) 1535-1544
29. Chu Y., Wang L.X., Yang G., Ross H.J., Urba W.J., Prell R., Jooss K., Xiong S., and Hu H.M. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J. Immunother. 29 4 (2006) 367-380
30. Chung T.D., Mauceri H.J., Hallahan D.E., Yu J.J., Chung S., Grdina W.L., Yajnik S., Kufe D.W., and Weichselbaum R.R. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 5 6 (1998) 344-349
31. Colombo M.P., and Forni G. Immunotherapy. I: Cytokine gene transfer strategies. Cancer Metastasis Rev. 16 3-4 (1997) 421-432
32. Coughlin C.M., Wysocka M., Kurzawa H.L., Lee W.M., Trinchieri G., and Eck S.L. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55 21 (1995) 4980-4987
33. Coughlin C.M., Salhany K.E., Gee M.S., LaTemple D.C., Kotenko S., Ma X., Gri G., Wysocka M., Kim J.E., Liu L., Liao F., Farber J.M., Pestka S., Trinchieri G., and Lee W.M. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9 1 (1998) 25-34
34. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
35. De Bouard S., Guillamo J.S., Christov C., Lefevre N., Brugieres P., Gola E., Devanz P., Indraccolo S., and Peschanski M. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum. Gene Ther. 14 9 (2003) 883-895
36. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., and Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 3 (2005) 211-226
37. Deshmukh P., Glick R.P., Lichtor T., Moser R., and Cohen E.P. Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice. J. Neurosurg. 94 2 (2001) 287-292
38. Dezfouli S., Hatzinisiriou I., and Ralph S.J. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells. Immunol. Cell Biol. 81 6 (2003) 459-471
39. Dias S., Boyd R., and Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int. J. Cancer 78 3 (1998) 361-365
40. Dinney C.P., Bielenberg D.R., Perrotte P., Reich R., Eve B.Y., Bucana C.D., and Fidler I.J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 58 4 (1998) 808-814
41. Divino C.M., Chen S.H., Yang W., Thung S., Brower S.T., and Woo S.L. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res. Treat. 60 2 (2000) 129-134
42. Dome B., Timar J., Dobos J., Meszaros L., Raso E., Paku S., Kenessey I., Ostoros G., Magyar M., Ladanyi A., Bogos K., and Tovari J. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 66 14 (2006) 7341-7347
43. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4 1 (2004) 11-22
44. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., and Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90 8 (1993) 3539-3543
45. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 11 (2006) 836-848
46. Dvorak H.F., and Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl. Cancer Inst. 81 7 (1989) 497-502
47. Egle A., Villunger A., Kos M., Bock G., Gruber J., Auer B., and Greil R. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur. J. Immunol. 26 12 (1996) 3119-3126
48. Eguchi J., Hiroishi K., Ishii S., and Mitamura K. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing. Cancer Immunol. Immunother. 52 6 (2003) 378-386
49. Elenbaas B., and Weinberg R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264 1 (2001) 169-184
50. Emtage P.C., Wan Y., Hitt M., Graham F.L., Muller W.J., Zlotnik A., and Gauldie J. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther. 10 5 (1999) 697-709
51. Enzler T., Gillessen S., Manis J.P., Ferguson D., Fleming J., Alt F.W., Mihm M., and Dranoff G. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J. Exp. Med. 197 9 (2003) 1213-1219
52. Fathallah-Shaykh H.M., Kafrouni A.I., Zhao L.J., Smith G.M., and Forman J. Gene transfer into brain parenchyma elicits antitumor effects. Cancer Res. 60 7 (2000) 1797-1799
53. Fearon E.R., Pardoll D.M., Itaya T., Golumbek P., Levitsky H.I., Simons J.W., Karasuyama H., Vogelstein B., and Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60 3 (1990) 397-403
54. Ferrantini M., Giovarelli M., Modesti A., Musiani P., Modica A., Venditti M., Peretti E., Lollini P.L., Nanni P., Forni G., et al. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J. Immunol. 153 10 (1994) 4604-4615
55. Fitzpatrick F.A. Inflammation, carcinogenesis and cancer. Int. Immunopharmacol. 1 9-10 (2001) 1651-1667
56. Fleischmann C.M., Stanton G.J., and Fleischmann Jr. W.R. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. 16 10 (1996) 805-812
57. Forni G., Cavallo F., Consalvo M., Allione A., Dellabona P., Casorati G., and Giovarelli M. Molecular approaches to cancer immunotherapy. Cytokines Mol. Ther. 1 4 (1995) 225-248
58. Fujii S., Huang S., Fong T.C., Ando D., Burrows F., Jolly D.J., Nemunaitis J., and Hoon D.S. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther. 7 9 (2000) 1220-1230
59. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13 3 (1995) 688-696
60. Gaken J.A., Hollingsworth S.J., Hirst W.J., Buggins A.G., Galea-Lauri J., Peakman M., Kuiper M., Patel P., Towner P., Patel P.M., Collins M.K., Mufti G.J., Farzaneh F., and Darling D.C. Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. Hum. Gene Ther. 8 4 (1997) 477-488
61. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M., and Stern P.L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18 2 (1997) 89-95
62. Gillessen S., Naumov Y.N., Nieuwenhuis E.E., Exley M.A., Lee F.S., Mach N., Luster A.D., Blumberg R.S., Taniguchi M., Balk S.P., Strominger J.L., Dranoff G., and Wilson S.B. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc. Natl. Acad. Sci. USA 100 15 (2003) 8874-8879
63. Gollob J.A., Mier J.W., and Atkins M.B. Clinical use of systemic IL-12 therapy. Cancer Chemother. Biol. Response Modif. 19 (2001) 353-369
64. Golumbek P.T., Lazenby A.J., Levitsky H.I., Jaffee L.M., Karasuyama H., Baker M., and Pardoll D.M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254 5032 (1991) 713-716
65. Goon P.K., Lip G.Y., Boos C.J., Stonelake P.S., and Blann A.D. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8 2 (2006) 79-88
66. Griscelli F., Opolon P., Saulnier P., Mami-Chouaib F., Gautier E., Echchakir H., Angevin E., Le Chevalier T., Bataille V., Squiban P., Tursz T., and Escudier B. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther. 10 5 (2003) 386-395
67. Gyorffy S., Palmer K., Podor T.J., Hitt M., and Gauldie J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J. Immunol. 166 10 (2001) 6212-6217
68. Hanada K., Tsunoda R., and Hamada H. GM-CSF-induced in vivo expansion of splenic dendritic cells and their strong costimulation activity. J. Leukoc. Biol. 60 2 (1996) 181-190
69. Hao S., Su L., Guo X., Moyana T., and Xiang J. A novel approach to tumor suppression using microencapsulated engineered J558/TNF-alpha cells. Exp. Oncol. 27 1 (2005) 56-60
70. Hayakawa Y., Takeda K., Yagita H., Smyth M.J., Van Kaer L., Okumura K., and Saiki I. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100 5 (2002) 1728-1733
71. Hazama S., Noma T., Wang F., Iizuka N., Ogura Y., Yoshimura K., Inoguchi E., Hakozaki M., Hirose K., Suzuki T., and Oka M. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo. Br. J. Cancer 80 9 (1999) 1420-1426
72. Hendren S.K., Prabakaran I., Buerk D.G., Karakousis G., Feldman M., Spitz F., Menon C., and Fraker D.L. Interferon-beta gene therapy improves survival in an immunocompetent mouse model of carcinomatosis. Surgery 135 4 (2004) 427-436
73. Hess S.D., Egilmez N.K., Bailey N., Anderson T.M., Mathiowitz E., Bernstein S.H., and Bankert R.B. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J. Immunol. 170 1 (2003) 400-412
74. Hiroishi K., Tuting T., and Lotze M.T. IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J. Immunol. 164 2 (2000) 567-572
75. Hottiger M.O., Dam T.N., Nickoloff B.J., Johnson T.M., and Nabel G.J. Liposome-mediated gene transfer into human basal cell carcinoma. Gene Ther. 6 12 (1999) 1929-1935
76. Hsieh C.L., Pang V.F., Chen D.S., and Hwang L.H. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum. Gene Ther. 8 16 (1997) 1843-1854
77. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., and Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264 5161 (1994) 961-965
78. Huang S., Xie K., Bucana C.D., Ullrich S.E., and Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin. Cancer Res. 2 12 (1996) 1969-1979
79. Imagawa Y., Satake K., Kato Y., Tahara H., and Tsukuda M. Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model. Auris Nasus Larynx 31 3 (2004) 239-245
80. Indraccolo S., Minuzzo S., Gola E., Habeler W., Carrozzino F., Noonan D., Albini A., Santi L., Amadori A., and Chieco-Bianchi L. Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. Int. J. Biol. Markers 14 4 (1999) 251-256
81. Indraccolo S., Gola E., Rosato A., Minuzzo S., Habeler W., Tisato V., Roni V., Esposito G., Morini M., Albini A., Noonan D.M., Ferrantini M., Amadori A., and Chieco-Bianchi L. Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther. 9 13 (2002) 867-878
82. Indraccolo S., Habeler W., Tisato V., Stievano L., Piovan E., Tosello V., Esposito G., Wagner R., Uberla K., Chieco-Bianchi L., and Amadori A. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res. 62 21 (2002) 6099-6107
83. Indraccolo S., Tisato V., Tosello V., Habeler W., Esposito G., Moserle L., Stievano L., Persano L., Chieco-Bianchi L., and Amadori A. Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum. Gene Ther. 16 8 (2005) 957-970
84. Indraccolo S., Moserle L., Tisato V., Gola E., Minuzzo S., Roni V., Persano L., Chieco-Bianchi L., and Amadori A. Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors. Gene Ther. 13 12 (2006) 953-965
85. Iqbal Ahmed C.M., Johnson D.E., Demers G.W., Engler H., Howe J.A., Wills K.N., Wen S.F., Shinoda J., Beltran J., Nodelman M., Machemer T., Maneval D.C., Nagabhushan T.L., and Sugarman B.J. Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther. 8 10 (2001) 788-795
86. Ishii S., Hiroishi K., Eguchi J., Hiraide A., and Imawari M. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model. Gene Ther. 13 1 (2006) 78-87
87. Izawa J.I., Sweeney P., Perrotte P., Kedar D., Dong Z., Slaton J.W., Karashima T., Inoue K., Benedict W.F., and Dinney C.P. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin. Cancer Res. 8 4 (2002) 1258-1270
88. Jackaman C., Bundell C.S., Kinnear B.F., Smith A.M., Filion P., van Hagen D., Robinson B.W., and Nelson D.J. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J. Immunol. 171 10 (2003) 5051-5063
89. Jones R.K., Pope I.M., Kinsella A.R., Watson A.J., and Christmas S.E. Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther. 7 12 (2000) 1519-1528
90. Kaido T., Bandu M.T., Maury C., Ferrantini M., Belardelli F., and Gresser I. IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int. J. Cancer 60 2 (1995) 221-229
91. Kammertoens T., Schuler T., and Blankenstein T. Immunotherapy: target the stroma to hit the tumor. Trends Mol. Med. 11 5 (2005) 225-231
92. Kang W.K., Park C., Yoon H.L., Kim W.S., Yoon S.S., Lee M.H., Park K., Kim K., Jeong H.S., Kim J.A., Nam S.J., Yang J.H., Son Y.I., Baek C.H., Han J., Ree H.J., Lee E.S., Kim S.H., Kim D.W., Ahn Y.C., Huh S.J., Choe Y.H., Lee J.H., Park M.H., Kong G.S., Park E.Y., Kang Y.K., Bang Y.J., Paik N.S., Lee S.N., Kim S., Robbins P.D., Tahara H., Lotze M.T., and Park C.H. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 12 6 (2001) 671-684
93. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 9 (1999) 1451-1460
94. Kerbel R.S., and Hawley R.G. Interleukin 12: newest member of the antiangiogenesis club. J. Natl. Cancer Inst. 87 8 (1995) 557-559
95. Keyser J., Schultz J., Ladell K., Elzaouk L., Heinzerling L., Pavlovic J., and Moelling K. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. Exp. Dermatol. 13 6 (2004) 380-390
96. Khorana A.A., Rosenblatt J.D., Sahasrabudhe D.M., Evans T., Ladrigan M., Marquis D., Rosell K., Whiteside T., Phillippe S., Acres B., Slos P., Squiban P., Ross M., and Kendra K. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther. 10 4 (2003) 251-259
97. Kim T.S., Russell S.J., Collins M.K., and Cohen E.P. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int. J. Cancer 55 5 (1993) 865-872
98. Kohno T., Mizukami H., Suzuki M., Saga Y., Takei Y., Shimpo M., Matsushita T., Okada T., Hanazono Y., Kume A., Sato I., and Ozawa K. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res. 63 16 (2003) 5091-5094
99. Kowalczyk D.W., Wysocki P.J., and Mackiewicz A. Cancer immunotherapy using cells modified with cytokine genes. Acta Biochim. Pol. 50 3 (2003) 613-624
100. Kusumoto M., Umeda S., Ikubo A., Aoki Y., Tawfik O., Oben R., Williamson S., Jewell W., and Suzuki T. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother. 50 7 (2001) 373-381
101. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 4 (2001) 461-470
102. Lee S.M., Suen Y., Qian J., Knoppel E., and Cairo M.S. The regulation and biological activity of interleukin 12. Leuk. Lymphoma 29 5-6 (1998) 427-438
103. Lee N.C., Tsung K., and Norton J.A. Production of interferon-gamma by tumor-sensitized T cells is essential for interleukin-12-induced complete tumor eradication. Surgery 132 2 (2002) 365-368
104. Lejeune F.J., Lienard D., Matter M., and Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 6 (2006) 6
105. Lesimple T., Moisan A., Guille F., Leberre C., Audran R., Drenou B., and Toujas L. Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J. Immunother. 23 6 (2000) 675-679
106. Li Q., Li L., Li Z., Gong F., Feng W., Jiang X., and Xiong P. Antitumor effects of the fibroblasts transfected TNF-alpha gene and its mutants. J. Huazhong. Univ. Sci. Technol. Med. Sci. 22 2 (2002) 92-95
107. Lim M., and Simons J.W. Emerging concepts in GM-CSF gene-transduced tumor vaccines for human prostate cancer. Curr. Opin. Mol. Ther. 1 1 (1999) 64-71
108. Lopez C.A., Kimchi E.T., Mauceri H.J., Park J.O., Mehta N., Murphy K.T., Beckett M.A., Hellman S., Posner M.C., Kufe D.W., and Weichselbaum R.R. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol. Cancer Ther. 3 9 (2004) 1167-1175
109. Lotze M.T., Rubin J.T., Carty S., Edington H., Ferson P., Landreneau R., Pippin B., Posner M., Rosenfelder D., Watson C., et al. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum. Gene Ther. 5 1 (1994) 41-55
110. Lucas R., Kresse M., Latta M., and Wendel A. Tumor necrosis factor: how to make a killer molecule tumor-specific?. Curr. Cancer Drug Targets 5 6 (2005) 381-392
111. Lu W., Fidler I.J., and Dong Z. Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus-mediated interferon beta gene therapy. Cancer Res. 59 20 (1999) 5202-5208
112. Lu H., Ouyang W., and Huang C. Inflammation, a key event in cancer development. Mol. Cancer. Res. 4 4 (2006) 221-233
113. Mach N., Gillessen S., Wilson S.B., Sheehan C., Mihm M., and Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60 12 (2000) 3239-3246
114. Maio M., Fonsatti E., Lamaj E., Altomonte M., Cattarossi I., Santantonio C., Melani C., Belli F., Arienti F., Colombo M.P., and Parmiani G. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol. Immunother. 51 1 (2002) 9-14
115. Mauceri H.J., Hanna N.N., Wayne J.D., Hallahan D.E., Hellman S., and Weichselbaum R.R. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 56 19 (1996) 4311-4314
116. Mazzocchi A., Melani C., Rivoltini L., Castelli C., Del Vecchio M., Lombardo C., Colombo M.P., and Parmiani G. Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunol. Immunother. 50 4 (2001) 199-211
117. Mazzolini G., Qian C., Xie X., Sun Y., Lasarte J.J., Drozdzik M., and Prieto J. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther. 6 6 (1999) 514-522
118. Meazza R., Lollini P.L., Nanni P., De Giovanni C., Gaggero A., Comes A., Cilli M., Di Carlo E., Ferrini S., and Musiani P. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int. J. Cancer 87 4 (2000) 574-581
119. Mezhir J.J., Smith K.D., Posner M.C., Senzer N., Yamini B., Kufe D.W., and Weichselbaum R.R. Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 13 1 (2006) 1-6
120. Morini M., Albini A., Lorusso G., Moelling K., Lu B., Cilli M., Ferrini S., and Noonan D.M. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. Gene Ther. 11 3 (2004) 284-291
121. Morse M.A., Lyerly H.K., Clay T.M., Abdel-Wahab O., Chui S.Y., Garst J., Gollob J., Grossi P.M., Kalady M., Mosca P.J., Onaitis M., Sampson J.H., Seigler H.F., Toloza E.M., Tyler D., Vieweg J., and Yang Y. Immunotherapy of surgical malignancies. Curr. Probl. Surg. 41 1 (2004) 15-132
122. Mule J.J., Yang J.C., Afreniere R.L., Shu S.Y., and Rosenberg S.A. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J. Immunol. 139 1 (1987) 285-294
123. Mundt A.J., Vijayakumar S., Nemunaitis J., Sandler A., Schwartz H., Hanna N., Peabody T., Senzer N., Chu K., Rasmussen C.S., Kessler P.D., Rasmussen H.S., Warso M., Kufe D.W., Gupta T.D., and Weichselbaum R.R. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin. Cancer Res. 10 17 (2004) 5747-5753
124. Musiani P., Modesti A., Giovarelli M., Cavallo F., Colombo M.P., Lollini P.L., and Forni G. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today 18 1 (1997) 32-36
125. Nagakawa H., Shimozato O., Yu L., Takiguchi Y., Tatsumi K., Kuriyama T., and Tagawa M. Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts. Scand. J. Immunol. 60 5 (2004) 449-454
126. Naka T., Sugamura K., Hylander B.L., Widmer M.B., Rustum Y.M., and Repasky E.A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62 20 (2002) 5800-5806
127. Nakayama T., Yao L., and Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J. Clin. Invest. 114 9 (2004) 1317-1325
128. Narvaiza I., Mazzolini G., Barajas M., Duarte M., Zaratiegui M., Qian C., Melero I., and Prieto J. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164 6 (2000) 3112-3122
129. Nasu Y., Bangma C.H., Hull G.W., Lee H.M., Hu J., Wang J., McCurdy M.A., Shimura S., Yang G., Timme T.L., and Thompson T.C. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 6 3 (1999) 338-349
130. Nelson W.G., Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Kim M., Weber C.E., Baccala A.A., Goeman M.A., Clift S.M., Ando D.G., Levitsky H.I., Cohen L.K., Sanda M.G., Mulligan R.C., Partin A.W., Carter H.B., Piantadosi S., and Marshall F.F. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol. 46 Suppl. (2000) S67-S72
131. Nemunaitis J., Bohart C., Fong T., Meyer W., Edelman G., Paulson R.S., Orr D., Jain V., O'Brien J., Kuhn J., Kowal K.J., Burkeholder S., Bruce J., Ognoskie N., Wynne D., Martineau D., and Ando D. Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. 5 5 (1998) 292-300
132. Nemunaitis J., Fong T., Robbins J.M., Edelman G., Edwards W., Paulson R.S., Bruce J., Ognoskie N., Wynne D., Pike M., Kowal K., Merritt J., and Ando D. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther. 6 4 (1999) 322-330
133. Okada H., and Kuwashima N. Gene therapy and biologic therapy with interleukin-4. Curr. Gene Ther. 2 4 (2002) 437-450
134. Okada H., Pollack I.F., Lieberman F., Lunsford L.D., Kondziolka D., Schiff D., Attanucci J., Edington H., Chambers W., Kalinski P., Kinzler D., Whiteside T., Elder E., and Potter D. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum. Gene Ther. 12 5 (2001) 575-595
135. Okada H., Villa L., Attanucci J., Erff M., Fellows W.K., Lotze M.T., Pollack I.F., and Chambers W.H. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther. 8 15 (2001) 1157-1166
136. Okada H., Lieberman F.S., Edington H.D., Witham T.F., Wargo M.J., Cai Q., Elder E.H., Whiteside T.L., Schold Jr. S.C., and Pollack I.F. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J. Neurooncol. 64 1-2 (2003) 13-20
137. Okamoto R., Ueno M., Yamada Y., Takahashi N., Sano H., Suda T., and Takakura N. Hematopoietic cells regulate the angiogenic switch during tumorigenesis. Blood 105 7 (2005) 2757-2763
138. Oliveira I.C., Sciavolino P.J., Lee T.H., and Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA 89 19 (1992) 9049-9053
139. Osanto S., Schiphorst P.P., Weijl N.I., Dijkstra N., Van Wees A., Brouwenstein N., Vaessen N., Van Krieken J.H., Hermans J., Cleton F.J., and Schrier P.I. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. 11 5 (2000) 739-750
140. Ozawa S., Shinohara H., Kanayama H.O., Bruns C.J., Bucana C.D., Ellis L.M., Davis D.W., and Fidler I.J. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 3 2 (2001) 154-164
141. Palmer K., Moore J., Everard M., Harris J.D., Rodgers S., Rees R.C., Murray A.K., Mascari R., Kirkwood J., Riches P.G., Fisher C., Thomas J.M., Harries M., Johnston S.R., Collins M.K., and Gore M.E. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. 10 8 (1999) 1261-1268
142. Parmiani G., Colombo M.P., Melani C., and Arienti F. Cytokine gene transduction in the immunotherapy of cancer. Adv. Pharmacol. 40 (1997) 259-307
143. Parney I.F., and Chang L.J. Cancer immunogene therapy: a review. J. Biomed. Sci. 10 1 (2003) 37-43
144. Parney I.F., Petruk K.C., Zhang C., Farr-Jones M., Sykes D.B., and Chang L.J. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther. 8 9 (1997) 1073-1085
145. Parney I.F., Farr-Jones M.A., Kane K., Chang L.J., and Petruk K.C. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12. Can. J. Neurol. Sci. 29 3 (2002) 267-275
146. Poehlein C.H., Hu H.M., Yamada J., Assmann I., Alvord W.G., Urba W.J., and Fox B.A. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J. Immunol. 170 4 (2003) 2004-2013
147. Qian C., and Prieto J. Gene therapy of cancer: induction of anti-tumor immunity. Cell Mol. Immunol. 1 2 (2004) 105-111
148. Qin Z., Schwartzkopff J., Pradera F., Kammertoens T., Seliger B., Pircher H., and Blankenstein T. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63 14 (2003) 4095-4100
149. Rakhmilevich A.L., Janssen K., Hao Z., Sondel P.M., and Yang N.S. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther. 7 6 (2000) 826-838
150. Rasmussen H., Rasmussen C., Lempicki M., Durham R., Brough D., King C.R., and Weichselbaum R. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther. 9 11 (2002) 951-957
151. Redlinger Jr. R.E., Shimizu T., Remy T., Alber S., Watkins S.C., and Barksdale Jr. E.M. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression. J. Pediatr. Surg. 38 2 (2003) 199-204
152. Rehman J., Li J., Orschell C.M., and March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107 8 (2003) 1164-1169
153. Ritter T., Lehmann M., and Volk H.D. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 16 1 (2002) 3-10
154. Rochlitz C.F., Jantscheff P., Bongartz G., Dietrich P.Y., Quiquerez A.L., Schatz C., Mehtali M., Courtney M., Tartour E., Dorval T., Fridman W.H., and Herrmann R. Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors. Adv. Exp. Med. Biol. 451 (1998) 531-537
155. Rochlitz C., Dreno B., Jantscheff P., Cavalli F., Squiban P., Acres B., Baudin M., Escudier B., Heinzerling L., Morant R., Herrmann R., Dietrich P.Y., and Dummer R. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther. 9 3 (2002) 289-295
156. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., and White D.E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210 4 (1989) 474-484 (discussion 484-475)
157. Rosenberg S.A., Lotze M.T., Yang J.C., Topalian S.L., Chang A.E., Schwartzentruber D.J., Aebersold P., Leitman S., Linehan W.M., Seipp C.A., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85 8 (1993) 622-632
158. Rossi I., Nicoletti G., Landuzzi L., Frabetti F., De Giovanni C., Nanni P., Musiani P., Ferrantini M., Belardelli F., and Lollini P.L. Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. Clin. Exp. Metastasis 16 2 (1998) 123-128
159. Rozera C., Carlei D., Lollini P.L., De Giovanni C., Musiani P., Di Carlo E., Belardelli F., and Ferrantini M. Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response. Am. J. Pathol. 154 4 (1999) 1211-1222
160. Sabzevari H., and Reisfeld R.A. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. Cancer Res. 53 20 (1993) 4933-4937
161. Saffran D.C., Horton H.M., Yankauckas M.A., Anderson D., Barnhart K.M., Abai A.M., Hobart P., Manthorpe M., Norman J.A., and Parker S.E. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity. Cancer Gene Ther. 5 5 (1998) 321-330
162. Saleh M., Davis I.D., and Wilks A.F. The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium. Int. J. Cancer 72 4 (1997) 664-672
163. Saleh M., Wiegmans A., Malone Q., Stylli S.S., and Kaye A.H. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J. Natl. Cancer Inst. 91 5 (1999) 438-445
164. Sampson J.H., Archer G.E., Ashley D.M., Fuchs H.E., Hale L.P., Dranoff G., and Bigner D.D. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA 93 19 (1996) 10399-10404
165. Sanches R., Kuiper M., Penault-Llorca F., Aunoble B., D'Incan C., and Bignon Y.J. Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy. Cancer Gene Ther. 7 5 (2000) 707-720
166. Santhanam S., Decatris M., and O'Byrne K. Potential of interferon-alpha in solid tumours: part 2. BioDrugs 16 5 (2002) 349-372
167. Santini S.M., Di Pucchio T., Lapenta C., Parlato S., Logozzi M., and Belardelli F. The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity. J. Interferon Cytokine Res. 22 11 (2002) 1071-1080
168. Schmelz K., Wieder T., Tamm I., Muller A., Essmann F., Geilen C.C., Schulze-Osthoff K., Dorken B., and Daniel P.T. Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene 23 40 (2004) 6743-6759
169. Senzer N., Mani S., Rosemurgy A., Nemunaitis J., Cunningham C., Guha C., Bayol N., Gillen M., Chu K., Rasmussen C., Rasmussen H., Kufe D., Weichselbaum R., and Hanna N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J. Clin. Oncol. 22 4 (2004) 592-601
170. Sgadari C., Angiolillo A.L., Cherney B.W., Pike S.E., Farber J.M., Koniaris L.G., Vanguri P., Burd P.R., Sheikh N., Gupta G., Teruya-Feldstein J., and Tosato G. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93 24 (1996) 13791-13796
171. Sgadari C., Angiolillo A.L., and Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87 9 (1996) 3877-3882
172. Sgadari C., Farber J.M., Angiolillo A.L., Liao F., Teruya-Feldstein J., Burd P.R., Yao L., Gupta G., Kanegane C., and Tosato G. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89 8 (1997) 2635-2643
173. Shawler D.L., Dorigo O., Gjerset R.A., Royston I., Sobol R.E., and Fakhrai H. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J. Immunother. Emphasis Tumor Immunol. 17 4 (1995) 201-208
174. Sidky Y.A., and Borden E.C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47 19 (1987) 5155-5161
175. Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Lim M., Weber C.E., Baccala A.A., Goemann M.A., Clift S.M., Ando D.G., Levitsky H.I., Cohen L.K., Sanda M.G., Mulligan R.C., Partin A.W., Carter H.B., Piantadosi S., Marshall F.F., and Nelson W.G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59 20 (1999) 5160-5168
176. Singh R.K., Gutman M., Bucana C.D., Sanchez R., Llansa N., and Fidler I.J. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA 92 10 (1995) 4562-4566
177. Smith K.M., Brewer J.M., Rush C.M., Riley J., and Garside P. In vivo generated Th1 cells can migrate to B cell follicles to support B cell responses. J. Immunol. 173 3 (2004) 1640-1646
178. Smyth M.J., Cretney E., Kershaw M.H., and Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202 (2004) 275-293
179. Sobol R.E., Shawler D.L., Carson C., Van Beveren C., Mercola D., Fakhrai H., Garrett M.A., Barone R., Goldfarb P., Bartholomew R.M., Brostoff S., Carlo D.J., Royston I., and Gold D.P. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin. Cancer Res. 5 9 (1999) 2359-2365
180. Soiffer R.J., Murray C., Shapiro C., Collins H., Chartier S., Lazo S., and Ritz J. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin. Cancer Res. 2 3 (1996) 493-499
181. Staba M.J., Mauceri H.J., Kufe D.W., Hallahan D.E., and Weichselbaum R.R. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 5 3 (1998) 293-300
182. Stewart A.K., Lassam N.J., Quirt I.C., Bailey D.J., Rotstein L.E., Krajden M., Dessureault S., Gallinger S., Cappe D., Wan Y., Addison C.L., Moen R.C., Gauldie J., and Graham F.L. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther. 6 3 (1999) 350-363
183. St John M.A., Li Y., Zhou X., Denny P., Ho C.M., Montemagno C., Shi W., Qi F., Wu B., Sinha U., Jordan R., Wolinsky L., Park N.H., Liu H., Abemayor E., and Wong D.T. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 130 8 (2004) 929-935
184. Streck C.J., Zhang Y., Miyamoto R., Zhou J., Ng C.Y., Nathwani A.C., and Davidoff A.M. Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta. Surgery 136 2 (2004) 183-189
185. Streck C.J., Dickson P.V., Ng C.Y., Zhou J., Gray J.T., Nathwani A.C., and Davidoff A.M. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clin. Cancer Res. 11 16 (2005) 6020-6029
186. Tahara H., and Lotze M.T. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 2 2 (1995) 96-106
187. Tahara H., Zeh III H.J., Storkus W.J., Pappo I., Watkins S.C., Gubler U., Wolf S.F., Robbins P.D., and Lotze M.T. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54 1 (1994) 182-189
188. Tahara H., Lotze M.T., Robbins P.D., Storkus W.J., and Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther. 6 12 (1995) 1607-1624
189. Tani K., Azuma M., Nakazaki Y., Oyaizu N., Hase H., Ohata J., Takahashi K., OiwaMonna M., Hanazawa K., Wakumoto Y., Kawai K., Noguchi M., Soda Y., Kunisaki R., Watari K., Takahashi S., Machida U., Satoh N., Tojo A., Maekawa T., Eriguchi M., Tomikawa S., Tahara H., Inoue Y., Yoshikawa H., Yamada Y., Iwamoto A., Hamada H., Yamashita N., Okumura K., Kakizoe T., Akaza H., Fujime M., Clift S., Ando D., Mulligan R., and Asano S. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol. Ther. 10 4 (2004) 799-816
190. Tartour E., Mehtali M., Sastre-Garau X., Joyeux I., Mathiot C., Pleau J.M., Squiban P., Rochlitz C., Courtney M., Jantscheff P., Herrmann R., Pouillart P., Fridman W.H., and Dorval T. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br. J. Cancer 83 11 (2000) 1454-1461
191. Tatsumi T., Takehara T., Kanto T., Kuzushita N., Ito A., Kasahara A., Sasaki Y., Hori M., and Hayashi N. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. Hepatology 30 2 (1999) 422-429
192. Teague R.M., Sather B.D., Sacks J.A., Huang M.Z., Dossett M.L., Morimoto J., Tan X., Sutton S.E., Cooke M.P., Ohlen C., and Greenberg P.D. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12 3 (2006) 335-341
193. Tepper R.I. The anti-tumour and proinflammatory actions of IL4. Res. Immunol. 144 8 (1993) 633-637
194. Tepper R.I., Pattengale P.K., and Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57 3 (1989) 503-512
195. Toy E.P., Chambers J.T., Kacinski B.M., Flick M.B., and Chambers S.K. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol. Oncol. 80 2 (2001) 194-200
196. Trudel S., Trachtenberg J., Toi A., Sweet J., Li Z.H., Jewett M., Tshilias J., Zhuang L.H., Hitt M., Wan Y., Gauldie J., Graham F.L., Dancey J., and Stewart A.K. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. 10 10 (2003) 755-763
197. Tuting T., Gambotto A., Baar J., Davis I.D., Storkus W.J., Zavodny P.J., Narula S., Tahara H., Robbins P.D., and Lotze M.T. Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther. 4 10 (1997) 1053-1060
198. Ugen K.E., Kutzler M.A., Marrero B., Westover J., Coppola D., Weiner D.B., and Heller R. Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther. 13 10 (2006) 969-974
199. van Horssen R., Ten Hagen T.L., and Eggermont A.M. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11 4 (2006) 397-408
200. van Kempen L.C., de Visser K.E., and Coussens L.M. Inflammation, proteases and cancer. Eur. J. Cancer 42 6 (2006) 728-734
201. Varghese S., Rabkin S.D., Liu R., Nielsen P.G., Ipe T., and Martuza R.L. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 13 3 (2006) 253-265
202. Veelken H., Mackensen A., Lahn M., Kohler G., Becker D., Franke B., Brennscheidt U., Kulmburg P., Rosenthal F.M., Keller H., Hasse J., Schultze-Seemann W., Farthmann E.H., Mertelsmann R., and Lindemann A. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int. J. Cancer 70 3 (1997) 269-277
203. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., and Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87 8 (1995) 581-586
204. Volpert O.V., Fong T., Koch A.E., Peterson J.D., Waltenbaugh C., Tepper R.I., and Bouck N.P. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 188 6 (1998) 1039-1046
205. von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., Wiedenmann B., Hocker M., and Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer. Inst. 95 6 (2003) 437-448
206. Wallenfriedman M.A., Conrad J.A., DelaBarre L., Graupman P.C., Lee G., Garwood M., Gregerson D.S., Jean W.C., Hall W.A., and Low W.C. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J. Neurosurg. 90 6 (1999) 1064-1071
207. Wang L., Wu W.Z., Sun H.C., Wu X.F., Qin L.X., Liu Y.K., Liu K.D., and Tang Z.Y. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 7 5 (2003) 587-594
208. Weber J.S., Jay G., Tanaka K., and Rosenberg S.A. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J. Exp. Med. 166 6 (1987) 1716-1733
209. Weiss J.M., Shivakumar R., Feller S., Li L.H., Hanson A., Fogler W.E., Fratantoni J.C., and Liu L.N. Rapid, in vivo, evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells. Cancer Gene Ther. 11 5 (2004) 346-353
210. Wigginton J.M., Gruys E., Geiselhart L., Subleski J., Komschlies K.L., Park J.W., Wiltrout T.A., Nagashima K., Back T.C., and Wiltrout R.H. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108 1 (2001) 51-62
211. Wilczynska U., Kucharska A., Szary J., and Szala S. Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer. Acta Biochim. Pol. 48 4 (2001) 1077-1084
212. Xu J., Zhou J.Y., and Wu G.S. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 66 20 (2006) 10092-10099
213. Yan L., Anderson G.M., DeWitte M., and Nakada M.T. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur. J. Cancer 42 6 (2006) 793-802
214. Yao L., Sgadari C., Furuke K., Bloom E.T., Teruya-Feldstein J., and Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93 5 (1999) 1612-1621
215. Ye J., Ortaldo J.R., Conlon K., Winkler-Pickett R., and Young H.A. Cellular and molecular mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line. J. Leukoc. Biol. 58 2 (1995) 225-233
216. Yu J.S., Burwick J.A., Dranoff G., and Breakefield X.O. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum. Gene Ther. 8 9 (1997) 1065-1072
217. Zhang X., Yang Z., Dong L., Papageorgiou A., McConkey D.J., and Benedict W.F. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther. (2006)
218. Zitvogel L., Tahara H., Cai Q., Storkus W.J., Muller G., Wolf S.F., Gately M., Robbins P.D., and Lotze M.T. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum. Gene Ther. 5 12 (1994) 1493-1506
219. Zitvogel L., Tahara H., Robbins P.D., Storkus W.J., Clarke M.R., Nalesnik M.A., and Lotze M.T. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155 3 (1995) 1393-1403